Tags

Type your tag names separated by a space and hit enter

Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.
Neurotherapeutics 2015; 12(1):132-42N

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and represents one of the highest unmet needs in medicine today. Drug development efforts for AD have been encumbered by largely unsuccessful clinical trials in the last decade. Drug repositioning, a process of discovering a new therapeutic use for existing drugs or drug candidates, is an attractive and timely drug development strategy especially for AD. Compared with traditional de novo drug development, time and cost are reduced as the safety and pharmacokinetic properties of most repositioning candidates have already been determined. A majority of drug repositioning efforts for AD have been based on positive clinical or epidemiological observations or in vivo efficacy found in mouse models of AD. More systematic, multidisciplinary approaches will further facilitate drug repositioning for AD. Some experimental approaches include unbiased phenotypic screening using the library of available drug collections in physiologically relevant model systems (e.g. stem cell-derived neurons or glial cells), computational prediction and selection approaches that leverage the accumulating data resulting from RNA expression profiles, and genome-wide association studies. This review will summarize several notable strategies and representative examples of drug repositioning for AD.

Authors+Show Affiliations

Department of Pathology and Cell Biology, and Taub Institute of Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, 10032, USA, twk16@columbia.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25549849

Citation

Kim, Tae-Wan. "Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease." Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, vol. 12, no. 1, 2015, pp. 132-42.
Kim TW. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. Neurotherapeutics. 2015;12(1):132-42.
Kim, T. W. (2015). Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, 12(1), pp. 132-42. doi:10.1007/s13311-014-0325-7.
Kim TW. Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease. Neurotherapeutics. 2015;12(1):132-42. PubMed PMID: 25549849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. A1 - Kim,Tae-Wan, PY - 2015/1/1/entrez PY - 2015/1/1/pubmed PY - 2016/1/20/medline SP - 132 EP - 42 JF - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics JO - Neurotherapeutics VL - 12 IS - 1 N2 - Alzheimer's disease (AD) is the most common cause of dementia and represents one of the highest unmet needs in medicine today. Drug development efforts for AD have been encumbered by largely unsuccessful clinical trials in the last decade. Drug repositioning, a process of discovering a new therapeutic use for existing drugs or drug candidates, is an attractive and timely drug development strategy especially for AD. Compared with traditional de novo drug development, time and cost are reduced as the safety and pharmacokinetic properties of most repositioning candidates have already been determined. A majority of drug repositioning efforts for AD have been based on positive clinical or epidemiological observations or in vivo efficacy found in mouse models of AD. More systematic, multidisciplinary approaches will further facilitate drug repositioning for AD. Some experimental approaches include unbiased phenotypic screening using the library of available drug collections in physiologically relevant model systems (e.g. stem cell-derived neurons or glial cells), computational prediction and selection approaches that leverage the accumulating data resulting from RNA expression profiles, and genome-wide association studies. This review will summarize several notable strategies and representative examples of drug repositioning for AD. SN - 1878-7479 UR - https://www.unboundmedicine.com/medline/citation/25549849/Drug_repositioning_approaches_for_the_discovery_of_new_therapeutics_for_Alzheimer's_disease_ L2 - https://dx.doi.org/10.1007/s13311-014-0325-7 DB - PRIME DP - Unbound Medicine ER -